| Model 1 95% C.I. | Model 2 95% C.I. | Model 3 95% C.I. | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
RAPA (1–7) | B | Lower | Upper | P | B | Lower | Upper | P | B | Lower | Upper | P |
PHQ-9 (0–27) | −0.06 | −0.08 | −0.04 | < 0.01 | −0.08 | −0.14 | −0.02 | 0.01 | −0.09 | −0.15 | −0.02 | 0.01 |
Gender (M/ F) | 0.33 | 0.18 | 0.48 | < 0.01 | 0.33 | 0.18 | 0.48 | < 0.01 | 0.29 | 0.10 | 0.47 | < 0.01 |
Patient group (SP/PP) | −0.01 | − 0.15 | 0.14 | 0.92 | −0.05 | − 0.22 | 0.12 | 0.55 | −0.02 | − 0.16 | 0.12 | 0.82 |
Age (Y) | −0.03 | −0.03 | − 0.02 | < 0.01 | − 0.03 | −0.04 | − 0.02 | < 0.01 | − 0.03 | −0.04 | − 0.02 | < 0.01 |
Smoking status (Y/ N) | 0.35 | 0.13 | 0.57 | < 0.01 | 0.35 | 0.13 | 0.56 | < 0.01 | 0.34 | 0.13 | 0.56 | < 0.01 |
PAM (0–13) | 0.02 | 0.01 | 0.03 | < 0.01 | 0.02 | 0.01 | 0.03 | < 0.01 | 0.02 | 0.01 | 0.03 | < 0.01 |
SP/PP group*PHQ-9 |  |  |  |  | 0.01 | −0.02 | 0.05 | 0.47 |  |  |  |  |
Gender*PHQ-9 |  |  |  |  |  |  |  |  | 0.02 | −0.02 | 0.05 | 0.44 |